A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506390-35-00

Acronym

4010-01-001

Enrollment

520

Registered

2024-03-18

Start date

2017-04-19

Completion date

Unknown

Last updated

2025-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Advanced Solid Tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Czechia, Denmark, France, Italy, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026